Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427060 | 1.00 | HTR6 (0.35) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28842926 | 0.98 | ALDH1A1 (0.35) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1961905 | 0.94 | ADRA1A (0.36) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL16823762 | 0.94 | ADRA1A (0.36) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29877044 | 0.93 | ALDH1A1 (0.38) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5912788 | 0.93 | ALDH1A1 (0.38) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16827275 | 0.93 | ALDH1A1 (0.38) | HTR6ADRA1AALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL12534 | 0.86 | HTR6 (0.52) | HTR6ADRA1AALDH1A1LMNA | |
| SCHEMBL12533 | 0.86 | HTR6 (0.52) | HTR6ADRA1AALDH1A1LMNA | |
| SCHEMBL18082909 | 0.86 | HTR6 (0.52) | HTR6ADRA1AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2022008426-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | HTR6 580/4885ADRA1A 17/4885ALDH1A1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.